journal article·2018-06-06Open access

Rapid on-Chip Assembly of Niosomes: Batch versus Continuous Flow Reactors

Sara Garcia-Salinas, Erico Himawan, Gracia Mendoza, Manuel Arruebo, Victor Sebastian

ACS Applied Materials & Interfaces· Volume 10· Issue 22

Abstract

The large-scale continuous production of niosomes remains challenging. The inherent drawbacks of batch processes such as large particle polydispersity and reduced batch-to-batch reproducibility are here overcome by using commercially available microfluidic reactors. Compared to the traditional batch-based film hydration method, herein, we demonstrate that it is possible to carry out the homogeneous, large-scale (up to 120 mg/min) production of niosomes using two different synthesis techniques (the thin film hydration method and the emulsification technique). Niosomes particle size can be controlled depending on the need by varying the synthesis temperature. The high cytocompatibility of the resulting niosomes was also demonstrated in this work on three different somatic cell lines. For the first time, the structure of the niosome multilamellar shell was also elucidated using high-resolution transmission electron microscopy (HR-STEM) as well as their colloidal stability over time (6 weeks) under different storage conditions. The morphology of cryo-protected or as-made niosomes was also evaluated by HR-STEM after freeze-drying. Finally, the dual ability of those synthetic, nonionic, surfactant-based vesicles to carry both hydrophilic and hydrophobic molecules was also here demonstrated by using laser scanning confocal microscopy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advancements in Transdermal Drug Delivery · Microfluidic and Bio-sensing Technologies · Advanced Drug Delivery Systems

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemical Engineering and Environmental Technology and Institute of Nanoscience of Aragon (INA), University of Zaragoza, Zaragoza 50009Spain

Aragon Health Research Institute (IIS Aragón), Zaragoza 50009, Spain

Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Madrid 28029, Spain

Funding

Centro de Investigaci?n Biom?dica en Red en Bioingenier?a, Biomateriales y Nanomedicina · European Regional Development Fund · Instituto de Salud Carlos III · FP7 Ideas: European Research Council

References (47)

Show source-provided references
1. 10.1016/j.addr.2013.08.00210.1016/j.addr.2013.08.002 ↗
2. 10.2174/138161282266616101011174110.2174/1381612822666161010111741 ↗
3. 10.1016/j.actbio.2017.01.00110.1016/j.actbio.2017.01.001 ↗
4. 10.1016/j.foodchem.2016.11.12910.1016/j.foodchem.2016.11.129 ↗
5. 10.1039/C6RA23620K10.1039/C6RA23620K ↗
6. 10.1016/S0168-3659(01)00432-110.1016/S0168-3659(01)00432-1 ↗
7. 10.1021/ie060446+10.1021/ie060446+ ↗
8. 10.1007/s11095-017-2146-y10.1007/s11095-017-2146-y ↗
9. 10.1038/nnano.2007.38710.1038/nnano.2007.387 ↗
10. 10.2147/IJN.S10881210.2147/IJN.S108812 ↗
11. 10.1002/smll.20130164110.1002/smll.201301641 ↗
12. 10.1016/j.cis.2013.11.01810.1016/j.cis.2013.11.018 ↗
13. 10.1016/S0378-5173(98)00169-010.1016/S0378-5173(98)00169-0 ↗
14. 10.1016/S1773-2247(06)50021-810.1016/S1773-2247(06)50021-8 ↗
15. 10.4103/0110-5558.7643510.4103/0110-5558.76435 ↗
16. 10.1021/acsomega.7b0074410.1021/acsomega.7b00744 ↗
17. 10.1021/acs.jpcb.5b0976110.1021/acs.jpcb.5b09761 ↗
18. Kitaoka M. · 2016 · 34910.1007/978-1-4939-3121-7_18 ↗
19. 10.1039/b821324k10.1039/b821324k ↗
20. 10.1080/00914037.2017.133262310.1080/00914037.2017.1332623 ↗
21. 10.1021/la904616s10.1021/la904616s ↗
22. 10.1016/j.jconrel.2014.04.01510.1016/j.jconrel.2014.04.015 ↗
23. 10.1016/j.ijpharm.2017.02.00710.1016/j.ijpharm.2017.02.007 ↗
24. 10.1016/j.ijpharm.2007.11.03710.1016/j.ijpharm.2007.11.037 ↗
25. 10.1021/acs.chemmater.5b0232310.1021/acs.chemmater.5b02323 ↗
26. 10.1016/j.ijpharm.2016.11.01510.1016/j.ijpharm.2016.11.015 ↗
27. 10.1016/j.cej.2017.02.00310.1016/j.cej.2017.02.003 ↗
28. 10.1021/nl801736q10.1021/nl801736q ↗
29. 10.1016/j.apsusc.2016.02.09210.1016/j.apsusc.2016.02.092 ↗
30. 10.1021/jp403724g10.1021/jp403724g ↗
31. 10.1016/j.ijpharm.2005.05.00910.1016/j.ijpharm.2005.05.009 ↗
32. 10.1006/jcis.2001.752010.1006/jcis.2001.7520 ↗
33. 10.5012/bkcs.2013.34.3.94610.5012/bkcs.2013.34.3.946 ↗
34. 10.1016/j.ijpharm.2008.05.03110.1016/j.ijpharm.2008.05.031 ↗
35. 10.1016/j.foodchem.2016.11.12910.1016/j.foodchem.2016.11.129 ↗
36. 10.1016/j.msec.2015.06.04910.1016/j.msec.2015.06.049 ↗
37. 10.1016/S0006-3495(01)75914-010.1016/S0006-3495(01)75914-0 ↗
38. 10.1016/j.colsurfb.2013.10.00910.1016/j.colsurfb.2013.10.009 ↗
39. 10.1038/srep4150310.1038/srep41503 ↗
40. Biswal S. · Int. J. Pharm. Sci. Nanotech. · 2008 · 1 · 1
41. Bhaskaran S. · Acta Pharm. Sci. · 2009 · 51 · 27
42. 10.1248/cpb.32.244210.1248/cpb.32.2442 ↗
43. Part 5: Tests for in Vitro cytotoxicity ISO 10993-5:2009—Biological Evaluation of Medical Devices; http://www.iso.org/iso/catalogue_detail.htm?csnumber=36406 (accessed Feb 1 2018).
44. 10.1146/annurev.immunol.17.1.59310.1146/annurev.immunol.17.1.593 ↗
45. 10.1155/2016/649295310.1155/2016/6492953 ↗
46. 10.3109/1061186X.2012.71684610.3109/1061186X.2012.716846 ↗
47. 10.1016/j.jconrel.2012.09.01810.1016/j.jconrel.2012.09.018 ↗